Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 6/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 6/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 6/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 6/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581978 | 0.90 | P2RX3 (0.37) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPSR1 | |
| SCHEMBL15887150 | 0.87 | NPSR1 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPSR1 | |
| SCHEMBL2219998 | 0.87 | LMNA (0.44) | NPSR1P2RX3ALDH1A1LMNAMAPT | |
| SCHEMBL2217150 | 0.87 | NPSR1 (0.37) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1NPSR1 | |
| SCHEMBL2218752 | 0.85 | NPSR1 (0.46) | NPSR1P2RX3ALDH1A1LMNAMAPT | |
| SCHEMBL1580227 | 0.83 | P2RX3 (0.39) | NPSR1P2RX3ALDH1A1LMNAMAPT | |
| SCHEMBL15887168 | 0.81 | NPSR1 (0.41) | NPSR1P2RX3P2RX7ALDH1A1LMNA | |
| SCHEMBL2217581 | 0.80 | SYK (0.40) | P2RX3 | |
| SCHEMBL14482806 | 0.79 | PRKD1 (0.35) | NPSR1LMNA | |
| SCHEMBL2219260 | 0.78 | MEN1 (0.42) | NPSR1P2RX3METP2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | TYMS, TYMP, DCTPP1 | GUCY1B2 4470/4885GUCY1A2 4467/4885GUCY1A1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.